bio compatibility performance
TRANSCRIPT
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 1/60
Click to edit Master subtitle style
BiocompatibilityPerformance
Materials and Coatings
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 2/60
Kardium Confidential 2009
ISO 10993 -1
•
2 Terms and definitions• For the purposes of this document, the following terms and definitions apply.
• 2.1
• medical device
• any instrument, apparatus, appliance, material or other article, includingsoftware, whether used alone or in
• combination, intended by the manufacturer to be used for human beingssolely or principally for the purpose of:
• diagnosis, prevention, monitoring, treatment or alleviation of disease;
• diagnosis, monitoring, treatment, alleviation of or compensation for aninjury or handicap;
•
investigation, replacement or modification of the anatomy or of aphysiological process;
• control of conception;
• and which does not achieve its principal intended action in or on the humanbody by pharmacological,
• immunological or metabolic means, but which may be assisted in its function
by such means
• NOTE 1 Devices are different from dru s and their biolo ical evaluation
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 3/60
Kardium Confidential 2009
General Principles forBiological Evaluation
• 3.2 In the selection of materials to be used in device manufacture,the first consideration should be fitness for purpose with regard tocharacteristics and properties of the material, which includechemical, toxicological, physical, electrical, morphological andmechanical properties.
• 3.3 The following should be considered for their relevance to theoverall biological evaluation of the device:
• a) the material(s) of manufacture;
• b) intended additives, process contaminants and residues;
• c) leachable substances;
• d) degradation products;
• e) other components and their interactions in the final product;
• f) the properties and characteristics of the final product.
• NOTE If appropriate, identification and quantification of extractablechemical entities of the final product should precede biological
evaluation .
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 4/60
Kardium Confidential 2009
Categorization of MedicalDevices
•
Nature of Contact
• Duration of contact
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 5/60
Kardium Confidential 2009
Nature of contact
• Non Contact Devices (Not part of ISO10993)
•
Surface Contacting Devices (Skin,mucosal membranes, breached orcompromised surfaces).
•
External Communicating Devices.• Implant Devices.
l C i i
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 6/60
Kardium Confidential 2009
External CommunicatingDevices
• a) blood path, indirect: devices that contact the blood path at onepoint and serve as a conduit for entry into the vascular system;examples include solution administration sets, extension sets,
transfer sets and blood administration sets;
• b) tissue/bone/dentin: devices that contact tissue, bone orpulp/dentin systems; examples include laparoscopes, arthroscopes,draining systems, dental cements, dental filling materials and skinstaples;
• c) circulating blood: devices that contact circulating blood;examples include intravascular catheters, temporary pacemakerelectrodes, oxygenators, extracorporal oxygenator tubing andaccessories, dialysers, dialysis tubing and accessories,
haemoadsorbents and immunoadsorbents.
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 7/60
Kardium Confidential 2009
Duration of Contact
• a) Limited exposure (A): devices whosesingle or multiple use or contact is likely tobe up to 24 h;
• b) Prolonged exposure (B): devices whosesingle, multiple or long-term use orcontact is likely to exceed 24 h but not 30
days;
• c) Permanent contact (C): devices whosesingle, multiple or long-term use orcontact exceeds 30 days.
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 8/60
Kardium Confidential 2009
Canopus Device (Summary)
• It is an External CommunicatingDevice.
• It is in Contact with Circulating Blood.
• It is a Device with Limited Exposure(< 24 h)
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 9/60
Kardium Confidential 2009
Testing (General)
• Testing shall be performed on the finalproduct, or on representative samplestaken from the final product or from
materials processed in the same manneras the final product.• The existing information based on the
literature, experience and non-clinical
tests;• The protection of humans is the primary
goal of this document, a secondary goalbeing to ensure animal welfare and to
minimize the number and exposure of test
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 10/60
Kardium Confidential 2009
Testing (Detail)
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 11/60
Kardium Confidential 2009
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 12/60
Kardium Confidential 2009
Testing (Detail)
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 13/60
Kardium Confidential 2009
Supplementary Test
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 14/60
Kardium Confidential 2009
ISO Standards
• ISO 10993 -4 Haemocompatibility.
• ISO 10993 -5 In Vitro Cytotoxicity.
• ISO 10993 -10 Sensitization &Irritation.
• ISO 10993 -11 Systematic Toxicity.
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 15/60
Kardium Confidential 2009
More ISO Standards
• ISO 10993 - 2 Animal Welfare.• ISO 10993 - 7 Ethylene Oxide
Sterilization.• ISO 10993 -12 Sample Preparations.• ISO 10993 -13 Degradation Products
from Polymers.• ISO 10993 -15 Degradation from
Metals and
Alloys.
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 16/60
Kardium Confidential 2009
ISO 10993 -5
• This part of ISO 10993 describes testmethods to assess the in vitro cytotoxicityof medical devices.
•
These methods specify the incubation of cultured cells either directly or throughdiffusion
a) with extracts of a device, and/or
b) in contact with a device.• These methods are designed to determine
the biological response of mammaliancells in vitro using appropriate biologicalparameters.
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 17/60
Kardium Confidential 2009
ISO 10993 -10
• This part of ISO 10993 describes theprocedure for the assessment of medicaldevices and their constituent materials
with regard to their potential to produceirritation and delayed-typehypersensitivity.
This part of ISO 10993 includes
a) pretest considerations,b) details of the test procedures, and
c) key factors for the interpretation of
the results.
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 18/60
Kardium Confidential 2009
ISO 10993 -11
• This part of ISO 10993 specifies requirements andgives guidance on procedures to be followed in theevaluation of the potential for medical devicematerials to cause adverse systemic reactions.
• Systemic toxicity
Toxicity that is not limited to adverse effects at thesite of contact between the body and the device
• Acute systemic toxicity
Adverse effects occurring at any time after single,multiple or continuous exposures of a test sample
within 24 h
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 19/60
Kardium Confidential 2009
ISO 10993 -4
• This part of ISO 10993 provides general requirements forevaluating the interactions of medical devices with blood.It describes:
a) a classification of medical and dental devices that areintended for use in contact with blood, based on the intendeduse and duration of contact as defined in ISO 10993-1,
b) the fundamental principles governing the evaluation of the interaction of devices with blood,
c) the rationale for structured selection of tests accordingto specific categories, together with the principles andscientific basis of these tests.
• Detailed requirements for testing cannot be specifiedbecause of limitations in the knowledge and precision of tests
•
For interactions of devices with blood. This part of ISO10993 describes biological evaluation in general terms and
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 20/60
Kardium Confidential 2009
Skip testing ????
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 21/60
Kardium Confidential 2009
Decision tree for testing
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 22/60
Kardium Confidential 2009
Haemocopatibility tests
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 23/60
Kardium Confidential 2009
Minimun Test
Amendtment 1 to ISO
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 24/60
Kardium Confidential 2009
Amendtment 1 to ISO10993-4
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 25/60
Kardium Confidential 2009
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 26/60
Kardium Confidential 2009
Thrombosis Metrics
• Percentage of occlusion.
• Flow reduction.
• Gravimetric analysis.
•
Pressure drop across device.• Retrieval and examination of device.
• Autopsy of distal organs.
• Antibody binding. (measuring the amount of
labeled antibody specific for fibrin(ogen) orplatelet membrane receptors).
• Light microscopy and ESM.
• Imaging techniques (ultrasound, CT, MRI etc).
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 27/60
Kardium Confidential 2009
Haemolysis
• The main event after haemolysis isthe release of hemoglobin.
•
This is regarded as an especiallysignificant screening test because if this test is properly performed, anelevated plasma hemoglobin level
indicates haemolysis and reflectserythrocyte membrane fragility incontact with materials and devices.
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 28/60
Kardium Confidential 2009
Haemolysis Causes• Mechanical Forces:
– Osmotic Pressure. – Material Properties:
• Surface Morphology• Surface Chemistry and Energy• Cell Wall interaction• Air Entrainment
– Rheology• Shear Forces• Friction• Flow Stability
• Biological Factors (Changes to the membrane structure withchanges to elastic and permeability properties):
– Chemicals
– Toxins
– pH
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 29/60
Kardium Confidential 2009
Mechanical Haemolysis
•
Mechanical forces — PressureThe erythrocyte membrane is a semi permeable
membrane. A pressure differential will occur whentwo solutions of
different concentrations are separated by such amembrane. Osmotic pressure occurs when themembrane is
impermeable to passive solute movement. Thesepressure differentials can cause erythrocyte swelling
and cell
membrane rupture with release of freehemoglobin.
Vo = Red Blood Cell Volume in Isotonic Solution
V = Volume of a Red Blood Cell in a non Isotonic
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 30/60
Kardium Confidential 2009
Osmotic pressure
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 31/60
Kardium Confidential 2009
Mechanical Haemolysis
• Rheology
• It is an emulsion
• Non- Newtonian behavior
Duration of blood contact
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 32/60
Kardium Confidential 2009
Duration of blood contactand Surface area
• The chance to thrombus formationand embolization of the formedthrombi during manipulation of the
device is proportional to the contacttime between the device and theblood.
•
Devices with large surface areas maycause the destruction orconsumption of circulating bloodcells and proteins near the surface of the device lowerin their
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 33/60
Kardium Confidential 2009
Surface Roughness Example
A rough surface has ahigher affinity forplatelet attachmentand cause micro-
turbulence at thesurface.
Anionic or cationiccharge on the surface
can influence plasmaprotein adhesion
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 34/60
Kardium Confidential 2009
Surface chemistry Example
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 35/60
Kardium Confidential 2009
Blood Flow Dynamics
• The device can affect the dynamicsof flow at or near the device surface
• In areas of turbulence, platelets can
be forced to the surface of the devicecausing activation and aggregation
• In general, the more complex the
device geometry, the greater thechance of turbulence, stagnantregions and haemo-incompatibility
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 36/60
Kardium Confidential 2009
Blood flow dynamics
• Slow flow or stagnant systems(veins) produce “red thrombus” =red cells with lots of fibrin
• High flow systems (arteries) produce“white thrombus” = lots of plateletsand a little of fibrin
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 37/60
Kardium Confidential 2009
Intrinsic Coagulation Path
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 38/60
Kardium Confidential 2009
Extrinsic Coagulation Path
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 39/60
Kardium Confidential 2009
Coagulation Factors
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 40/60
Kardium Confidential 2009
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 41/60
Kardium Confidential 2009
• Thus, heparin is not itself an inhibitor;instead, it acts as a catalyst by convertingAT (Antithrombin) from a slow into a highlypotent anti coagulant, without beingconsumed in the inhibitory process.
This catalytic action is fundamental to the
creation of a stable non thrombogenicsurface, as the immobilized heparin is notexhausted or consumed in contact withblood, but maintains its catalytic activity.
Pr m ng to Cover mater a
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 42/60
Kardium Confidential 2009
Pr m ng to Cover mater aSurface and to attach
Heparin Molecules
i C i
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 43/60
Kardium Confidential 2009
Heparin Coating
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 44/60
Kardium Confidential 2009
A ifi i l Bl d V l
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 45/60
Kardium Confidential 2009
Artificial Blood Vessel
Complement (immune)
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 46/60
Kardium Confidential 2009
Complement (immune)System
• Another host defense against artificial materialsand invading microorganisms is the complementsystem. Complement is activated by essentiallyany material, but is under strict control by
regulating factors on the cells of the hostorganism(“self”). As foreign (“non-self”) materialslack this regulatory function, complement has thecapacity to discriminate between “self” and “non-self.” Thus, the presence of any artificial surfacesin the blood circulation will cause some degree of complement activation. The principal outcome of this activation is an inflammatory reaction, whichis beneficial in the defense against infectious
agents but may represent a serious complication
MSD Bi di l
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 47/60
Kardium Confidential 2009
MSD Biomedical
• ComfortCoat® Hydrophiliccoating
• Excellent lubricity: reduces the
stiction and the friction forces andminimizes patient discomfort andtissue damage
•
Superior durability: better adhesionto the surface of the medical deviceand cohesion of the polymer matrix
•
Adhesion to many substrates: e.g.
MSD Bi di l
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 48/60
Kardium Confidential 2009
MSD Biomedical
• ComfortCoat® HemocompatibleAntimicrobial coating
• Antimicrobial activity: demonstrated
activity against E.Coli and S Aureus• Hemocompatibility: positive results in
hemocompatibility and
thrombogenicity tests• Excellent lubricity and superior
durability: reduces stiction and
friction and thus reduces patient
MSD Bi di l
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 49/60
Kardium Confidential 2009
MSD Biomedical
• VitroStealth® non-foulingcoating
• Excellent non-biofouling propertiesresult in reduction in proteinadsorption, nucleic acid adsorption,
bacterial and cellular adhesion• Crosslinking leads to extremely low
levels of extractables and leachables
DSM Bi di l
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 50/60
Kardium Confidential 2009
DSM Biomedical
• BioSpan Segmented Poliurethane•
Able to withstand millions of flexcycles.• Often chosen for cardiac assist
devices that must survive over 40millions cycles per year.
MSD Biomedical
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 51/60
Kardium Confidential 2009
MSD Biomedical
BioSpan SegmentedPolyurethane
Bi t
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 52/60
Kardium Confidential 2009
Biocoat
• HYDAK Advantages• Exceptionally hydrophilic
• Lubricious when wet, preventing trauma and tissueabrasion
• Abrasion resistant
• Very thin, flexible coatings can be applied
• Biocompatible
•
Non-thrombogenic• Prevents adhesion of platelets, proteins, and
microorganisms
• Carrier for bioactive substances to make –
anti-bacterial surfaces
Bi t
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 53/60
Kardium Confidential 2009
Biocoat
Bi t
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 54/60
Kardium Confidential 2009
Biocoat
Parylene Deposition Process
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 55/60
Kardium Confidential 2009
Parylene Deposition ProcessVacuum Vapor Deposition
Parylene Electrical
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 56/60
Kardium Confidential 2009
Parylene ElectricalProperties
Parylene Mechanical
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 57/60
Kardium Confidential 2009
Parylene MechanicalProperties
Parylene
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 58/60
Kardium Confidential 2009
Parylene
Parylene
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 59/60
Kardium Confidential 2009
Parylene
Pinhole free barrier to protectagainst body fluids as well asmoisture, chemicals and commongases
Parylene
8/4/2019 Bio Compatibility Performance
http://slidepdf.com/reader/full/bio-compatibility-performance 60/60
Parylene